NEO — NeoGenomics, Inc.

Summary of NeoGenomics, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $190 million, an 11% increase year-over-year.
• Full Year Revenue: $727 million, reflecting a 10% growth from 2024.
• Clinical Revenue: Grew 16% year-over-year in Q4 and 15% for the full year.
• Adjusted Gross Profit: Increased by $5.8 million (7%) in Q4, totaling $335 million for the year.
• Adjusted EBITDA: $13.4 million in Q4 (up 10%), with a full-year total of $43.4 million (up 9%).
• Cash Flow: Positive cash flow from operations of $1 million in Q4 and $5 million for the full year.
• Average Revenue per Test (AUP): Increased by 5% year-over-year in Q4, with a sequential increase of $12.

2. Strategic Updates and Business Highlights

• Growth Initiatives: Focus on Next-Generation Sequencing (NGS) and Minimal Residual Disease (MRD) testing, with the RADAR ST assay set for full clinical launch.
• Market Position: NeoGenomics holds over 25% market share in hematology testing and has expanded its lab network through the acquisition of Pathline.
• Product Launches: Five NGS products launched in 2023 contributed significantly to clinical revenue, with continued demand across all testing modalities.
• Sales Force Expansion: Increased the oncology sales team by 35, targeting community oncologists to drive further growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $793 million and $801 million, with a focus on gradual growth from RADAR ST and PANTRACER liquid tests.
• Adjusted EBITDA for 2026: Projected to be between $55 million and $57 million, representing a year-over-year growth of approximately 27% to 31%.
• Quarterly Growth Expectations: Anticipated growth rates of 10% in Q1, 8-9% in Q2, 9-10% in Q3, and slightly above 10% in Q4.

4. Bad News, Challenges, or Points of Concern

• Nonclinical Revenue Decline: Nonclinical revenue decreased by over 25% in Q4 and 24% for the full year, aligning with expectations but indicating a significant area of concern.
• Market Pressures: Ongoing softness in the pharma segment is expected to continue into 2026, with modest erosion anticipated.
• Operational Challenges: The company is rationalizing its exposure to lower-value tests, which may temporarily impact volume growth.
• Reimbursement Uncertainties: Delays in MolDX approvals for new indications could affect revenue growth from RADAR ST and PANTRACER liquid tests.

5. Notable Q&A Insights

• RADAR ST Launch: The full launch is scheduled for the end of January 2026, focusing initially on head and neck and specific breast cancer indications.
• Sales Force Productivity: The newly expanded sales team is showing increased productivity, with a notable rise in the number of oncologists ordering multiple tests.
• Competitive Landscape: Despite competition, NeoGenomics believes its comprehensive test menu and strong service levels position it favorably in the community oncology market.
• Long-Term Growth Strategy: The company is prioritizing high-value tests to improve margins and is cautious about entering low-value contracts, which could dilute profitability.

This summary encapsulates the key points discussed during the earnings call, highlighting NeoGenomics' financial performance, strategic initiatives, future outlook, and challenges faced in the evolving market landscape.